Drug side effects
brodalumab Side Effects
The reactions most often reported to the FDA for brodalumab (also sold as Siliq), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 1,890
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2013 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of brodalumab come from 1,890 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 1,890 reports to the FDA Adverse Event Reporting System (FAERS) for brodalumab (Siliq): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
1,890
Reports Mentioning Death
133
7.0% of reports — not proof the medicine caused the death
Hospitalizations
535
28.3% of reports
Top Indication
Psoriasis
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 133 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 72 |
| PSORIASIS | 11 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 8 |
| BLOOD PRESSURE INCREASED | 7 |
| PNEUMONIA | 7 |
| FALL | 6 |
| ASTHENIA | 5 |
| COUGH | 5 |
| COVID-19 | 5 |
| DISEASE RECURRENCE | 5 |
| FATIGUE | 5 |
| HEADACHE | 5 |
| HOSPITALISATION | 5 |
| ILLNESS | 5 |
| MALAISE | 5 |
| NEOPLASM MALIGNANT | 5 |
| PRURITUS | 5 |
| RENAL FAILURE | 5 |
Reactions in Hospitalization Reports
Top reactions in 535 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PSORIASIS | 147 |
| HOSPITALISATION | 57 |
| ARTHRALGIA | 45 |
| THERAPY INTERRUPTED | 43 |
| FALL | 41 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 37 |
| COVID-19 | 33 |
| FATIGUE | 31 |
| CONDITION AGGRAVATED | 30 |
| DISEASE RECURRENCE | 30 |
| HEADACHE | 29 |
| PNEUMONIA | 27 |
| PRURITUS | 27 |
| PAIN IN EXTREMITY | 26 |
| PATIENT DISSATISFACTION WITH TREATMENT | 25 |
| DIARRHOEA | 24 |
Nearby, Related Medications
What the FAERS Data Reveals About brodalumab Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 1,890 voluntary reports linked to brodalumab and its brand equivalents (Siliq), spanning 2013 through 2025. Of those, 133 (7.0%) listed death as an outcome and 535 (28.3%) involved hospitalization. The most common indication reported alongside adverse events was Psoriasis.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 46% were female and 54% male; age distribution skews toward 45-64, with 646 reports in that bracket. The single most reported reaction is psoriasis with 471 submissions, followed by arthralgia and fatigue.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to brodalumab's 1,890.
Read our methodology - how this data is sourced, computed, and verified.